Presentation, questions & the final decisionModule 08 · Negotiation, persuasion & integration
IGNITE EXTENDED / LESSON 40
Presentation, questions & the final decision
Can the audience understand, question and act on the decision?
A final presentation, question log and revised decision memo.
1
40 / OpeningPresentation, questions & the final decision
The decision and the learning goals
Answer a challenge directly with evidence and a material limitation.
Use rehearsal to test comprehension and timing.
State the action, resources and observation that will trigger review.
90-minute workshopOpening 5 minConcepts and original examples 35 minPractice 25 minDebrief 15 minReview 10 min
2
40 / TheoryPresentation, questions & the final decision
Preparation includes the audience’s questions
Questions reveal where the audience needs more information or disagrees with an assumption. Prepare by identifying the weakest consequential parts of the argument and the evidence available for each. A list of anticipated questions is useful when it leads to clearer reasoning.
Rehearse explaining the mechanism in plain language. Avoid memorizing a long answer that only loosely fits the question. The dialogue reading emphasizes helping the audience participate and connecting a response to the shared discussion.
3
40 / TheoryPresentation, questions & the final decision
A concise response can preserve the uncertainty
Begin by answering the question directly. Then give the evidence or reasoning needed to support the answer. State a limitation that materially affects the conclusion and connect it to an action or a decision boundary.
An unknown answer should remain unknown. Distinguish information you can supply later from uncertainty that requires new work. This allows the audience to assess the recommendation without rewarding false precision. A conditional recommendation can be appropriate when the next step is designed to obtain that evidence.
4
40 / TheoryPresentation, questions & the final decision
Open with the decision, not the feature inventory
State the recommendation and the audience’s role.
Explain the customer problem and the proposed benefit.
Show the evidence that makes the decision plausible.
Make the next action clear.
5
40 / TheoryPresentation, questions & the final decision
Numbers should carry an explanation
State units, periods and what is compared.
Distinguish observed results from forecasts and assumptions.
Trace important totals to drivers.
Show the uncertainty that could change the recommendation.
6
40 / Source insightPresentation, questions & the final decision
Linking each answer back to the conversation
The closing page of Abrahams's Monologue to Dialogue. It advises linking each answer to what the speaker said earlier and to other audience questions, and it closes by treating participation as a skill that can be prepared and facilitated.
Linking turns Q&A into part of the argument rather than a string of separate defenses. In an investor meeting, tie each answer back to the claim it tests (for example: 'that is the retention assumption on slide 5') so the partners see one connected case.
7
40 / Reading debriefPresentation, questions & the final decision
From Monologue to Dialogue / summary
Selected reading: PDF pages 3, 4, 6, 7, 8
Audience participation needs preparation and facilitation. The presenter helps people move from listening to contributing, then connects their questions and examples to the developing explanation.
A shared activity
The reading reframes presenting as working with an audience. This changes both the presenter’s anxiety and the way participation is invited.
Preparation for participation
Questions, relevant examples and familiar analogies help listeners see their connection to the topic before a discussion begins.
A clear invitation
People may hesitate because they fear judgment or do not know what is expected. A bounded prompt and thinking time lower that barrier.
A useful response
Paraphrase when helpful, answer the actual question and add a concrete example. Link the response back to earlier ideas so everyone can follow.
8
40 / Reading debriefPresentation, questions & the final decision
From Monologue to Dialogue / discussion
Selected reading: PDF pages 3, 4, 6, 7, 8
Critical points
Participation has a purpose
An activity earns its place by improving understanding or informing a decision. More audience speech does not by itself establish better learning.
Timing depends on the setting
The reading discusses taking questions during or after a talk. Choose according to the speaker’s capacity, the argument and the audience’s needs.
A boundary on confidence
A fluent answer still needs support. When the relevant observation is missing, identify the gap and the decision it affects.
9
40 / TheoryPresentation, questions & the final decision
Rehearsal tests comprehension and timing
A rehearsal can test whether another person follows the explanation, not just whether the speaker remembers it. Ask the listener to state the decision, the main supporting evidence and the largest unresolved uncertainty. Their reconstruction reveals gaps the speaker may not notice.
Practice transitions and answers aloud. Leave time for the audience to process a chart. A shorter explanation with a clear causal connection can be more informative than rapidly reading a dense page. The detailed slides remain available for questions and study.
10
40 / TheoryPresentation, questions & the final decision
The final decision includes a next observation
A business recommendation should state the action, resources, owner and review condition. It should also explain which evidence would make the team revise or stop the plan. This connects the final presentation to the entrepreneurial judgment introduced in the first lesson.
Evaluate the work on evidence, reasoning, trade-offs, integration and clarity. A polished delivery cannot repair an unsupported assumption, while a sound analysis can fail if the audience cannot understand the requested action. Use the final discussion to improve both.
11
40 / Deep divePresentation, questions & the final decision
Relay term-sheet options compared
The same $12M, compared on what the founders keep and what each path risks.
Founders hold 58.47% after the seed (10,000,000 of 17,102,041 fully diluted shares). The bridge terms are illustrative.
The bridge row shows only dilution. It adds months of execution risk and a fundraising signal that this comparison does not price.
Option
Terms
Founders post-A
Main risk
Accept as offered
$12M at $48M pre / $60M post, 1x non-participating, pari passu, no top-up
46.78% (Maya 24.33%, Daniel 22.45%)
The lead's 25% math invites a re-trade in diligence
Lead re-trades to 25%
$12M at $36M pre / $48M post
43.85%
Price falls after exclusivity
Pool shuffle
$48M headline pre, 10% post-money unallocated pool counted in pre
About 45.48% (effective pre about $46.7M)
Hidden dilution behind an unchanged headline
Push the price
For example, $54M pre
About 47.8% if no other term moves
Lead walks or answers with a pool top-up
Bridge, then raise the A
$3M post-money SAFE at $50M cap (6%), A later at pre-money P
58.47% x 0.94 x P/(P+12); equals 46.78% at P of about $68.6M
Longer gap, signaling, and metrics may not improve
12
40 / TheoryPresentation, questions & the final decision
A concise response to a challenge
During questions, the audience may challenge a weak link in the argument. Example: “How do you know customers will still use the scheduling tool after three months?”
01
Listen
Identify the concern before answering. This question is about sustained use, not whether participants liked the prototype. Clarify the period or population if the question is ambiguous.
02
Answer
Give the direct response first: “We do not yet have three-month retention evidence.” Do not replace the requested result with an enthusiastic interview quote.
03
Support
State what is known: two organizations paid for short pilots, and none has used the tool beyond two weeks. Explain the narrow conclusion those observations support.
04
Limit & act
Connect the gap to a decision: track retained use in the bounded pilot, review the agreed criteria and delay the larger commitment until the required evidence is available.
The response returns to the recommendation. If the challenge exposes a contradiction that invalidates the pilot, revise the action rather than defending the original wording.
13
40 / TheoryPresentation, questions & the final decision
The final recommendation should remain revisable
Identify the weakest link in the argument.
Name evidence that would overturn or refine the choice.
Define a next action that fits the resources available.
Record what the course changed in your reasoning.
14
40 / Source insightPresentation, questions & the final decision
Handling visuals and delivery in a team presentation
Page 3 of the Ignite team-presentation tips. It covers message titles instead of topic labels, a sequence for each visual (introduce, let it sink in, overview, discuss, summarize, remove), and delivery basics including pausing and choosing which slide stays up during Q&A.
The tip to choose carefully which slide stays up during Q&A, since it will be visible longest, is directly usable. For Relay, that slide should be the ask with its milestones and the options compared, not the logo slide.
15
40 / Reading debriefPresentation, questions & the final decision
Team presentation guidance / summary
Selected reading: PDF pages 1, 2, 3
The selected guidance connects a shared intent with audience analysis, a coherent sequence and rehearsed delivery. A team presentation needs one argument that remains understandable across speakers and visual aids.
A common intent
The team agrees on the result requested from the audience and the central message each segment supports.
Audience-oriented structure
The opening supplies the decision and a roadmap. Internal summaries and explicit transitions keep listeners oriented as the argument develops.
A coordinated team
Consistent terms, numbers and visual conventions support continuity. Rehearsal checks the handoffs and the total time needed.
Visuals support explanation
The guidance asks speakers to introduce a visual, orient the audience, discuss its detail and state its implication. Delivery gives the audience time to follow.
16
40 / Reading debriefPresentation, questions & the final decision
Team presentation guidance / discussion
Selected reading: PDF pages 1, 2, 3
Critical points
Live delivery and study
The reading favors concise visuals during a talk. This HTML also serves independent study, so a presenter can select the relevant pages while learners retain the detailed explanations.
Continuity of reasoning
Smooth speaker changes help only when the segments support the same recommendation. Check the logic across the handoff as well as its timing.
Questions need a conclusion
Plan how to return from discussion to the decision and next action. A presentation can lose its purpose if it ends with the last unanswered tangent.
17
40 / Current practicePresentation, questions & the final decision
Current practice: the Series A decision in 2025-2026
Relay's terms against the benchmarks
Carta reports a median 2025 Series A post-money valuation of $60M, identical to Relay's offer. For software companies in rounds raised in the six months before July 2026, Carta reports a median of about $80M on $14.4M raised. Benchmarks frame the negotiation, but the lead's own exit math matters more than the median.
Bridges are common but not neutral
Carta found that about 29% of seed and Series A deals in 2025 were bridges, and that the median gap from seed to Series A had grown to about 2.1 years. Investors are used to bridges, but a bridge chosen over a committed lead still has to be justified by the milestones it buys.
Compliance questions are moving targets
HHS proposed a major HIPAA Security Rule update in January 2025, adding requirements such as encryption, multifactor authentication and annual penetration testing. In July 2026 the federal regulatory agenda moved the expected final rule to July 2027. A health-data company should show diligence teams a security program that already meets the proposed controls, and should confirm current requirements with counsel.
40 / PracticePresentation, questions & the final decision
An evidence-based question session
Use the pilot proposal from lesson 39 or your own completed portfolio. The audience challenges customer representativeness, retention, acquisition cost, implementation capacity and the requested funding amount. Some answers require observations that do not yet exist.
Your task
Present for five minutes, answer questions for five, then revise the decision memo. For each answer, state the direct response, support and any consequential limitation. Record what changed.
19
40 / DebriefPresentation, questions & the final decision
Worked answer and reasoning
A strong response answers the actual question and identifies which evidence bears on it.
Unobserved retention remains unobserved. State the test and the decision that depends on its result rather than inventing a forecast.
The final memo states an action, owner, resources and a review condition. Revise the recommendation if a question exposes a material contradiction.
20
40 / Venture stepPresentation, questions & the final decision
Venture step: The partner meeting and the term-sheet decision
Relay · venture step 40
Relay presents to the lead's partnership. The term sheet: $12M at $48M pre ($60M post), 1x non-participating preferred, pari passu with the seed, no pool top-up. Post-A, Maya and Daniel would hold 46.78% together (24.33% and 22.45%). The lead's own VC math ($600M exit, a 10x target and 20% dilution expected at a Series B) implies it needs 25%, a $36M pre-money, so a re-trade in diligence is possible. The alternatives: negotiate the pre-money or pool, or raise a bridge and wait for better metrics.
Your task
Deliver a 10-minute presentation and 15 minutes of Q&A. Keep a question log (question, direct answer, evidence, gap). Submit a one-page decision memo: accept, negotiate or bridge, with the numbers, the owner, the conditions and the evidence that would reverse the decision.
21
40 / Venture stepPresentation, questions & the final decision
Venture step: worked reasoning
The options in numbers (cap-table figures from the bible). Accept: founders 58.47% x 0.8 = 46.78%. Lead re-trades to 25% ($12M at $36M pre): 58.47% x 0.75 = 43.85%. Pool shuffle (the 10% post-money unallocated pool counted in pre-money): founders 45.48%, effective pre-money about $46.7M. Bridge (illustrative $3M post-money SAFE at a $50M cap, 6%): founders = 58.47% x 0.94 x P/(P+12), equal to accepting only if the later A prices at a pre-money P of about $68.6M, 43% higher, after a longer gap and with bridge signaling risk.
Recommendation: accept the $48M pre and close quickly. Pushing the price is unwise when the lead's own model already wants 25%; the lead would likely answer with a pool top-up or a lower price after diligence. Negotiate structure instead: keep pari passu with the seed and 1x non-participating; size any pool to an 18-month hiring plan (the 8% unallocated post-A must cover it) and refuse a blanket 10% top-up; set a 5-seat board (2 founders, seed, Series A, 1 independent). Owner: Maya. Reverse the decision if diligence reopens the price below about $44M pre, or if group retention falls below the level the plan assumes.
Hard questions, part 1. 'Why won't ClinicOS bundle this and kill you?' It may bundle a basic waitlist. Northpoint chose Relay over the free bundle because fill rate, not a waitlist list, drives the revenue. Relay lists on the ClinicOS marketplace (30% revenue share) and stays multi-EHR so a single vendor cannot cut it off. Disclose the API dependency as the top risk. 'Your margin fell from 80% to 72%. Is this a software business?' Yes, at a lower LTV/CAC: 399 x 0.72 x 33 = about $9,480 against $2,400 CAC, or about 3.95. Show inference cost per conversation and the plan to handle routine replies without the LLM, stated as a forecast.
22
40 / Venture stepPresentation, questions & the final decision
Venture step: worked reasoning (continued)
Hard questions, part 2. 'How does this become a $100M-revenue company?' Not at $399 per clinic: that would need about 20,900 locations, about 55% of an illustrative 38,000. The path is Scheduler priced for groups, so the year-6 figure is the investor's case and depends on ARPA growth that is not yet observed. 'What happens to you at a $40M exit?' Series A takes its $12M preference (converting would give it 21.74% of outstanding shares, only $8.70M). The seed converts and shares the remaining $28M; Maya receives about $9.46M (L32), and the team keeps an incentive to build. 'You had a PHI incident.' A test message with a patient's full name went to a wrong number. Relay ran an incident review, minimized PHI in templates, added controls and documented the breach assessment with counsel. The application of HIPAA depends on current law and facts.
Hard questions, part 3. 'Why raise now rather than in nine months at a higher price?' A bridge needs about a 43% higher pre-money just to break even on dilution, and median seed-to-A gaps are already long. Taking committed capital now funds the group-sales motion. 'Is the 40% fill rate causal?' It comes from the L12 randomized comparison: cancellations at the same clinics assigned to Relay or the phone tree, fill source logged from the EHR, about $66,000 a year incremental per clinic. Cohorts are short, which is the next measurement. 'What would make you stop or change the plan?' If group net revenue retention or the fill rate falls below the thresholds in the memo for two consecutive quarters, Relay cuts hiring and revisits the segment.
23
40 / Deep divePresentation, questions & the final decision
Relay hard-question bank
For each question: the real concern, a direct answer, and the artifact that backs it.
Question
Real concern
Direct answer
Evidence
Why won't ClinicOS bundle this?
Platform dependency
It may bundle a basic waitlist. Fill rate drives revenue, and Relay is multi-EHR and listed on the marketplace.
L13, L14, Northpoint win (L38)
Is the 40% fill rate causal?
Selection and Hawthorne effects
Randomized against the phone tree at the same clinics, fill source logged from the EHR: about $66k a year incremental per clinic. Cohorts are still short.
L12
Why did gross margin fall to 72%?
AI cost structure
LLM inference. LTV/CAC is about 3.95. Plan: route routine replies away from the LLM (a forecast).
L10, L18
How is $100M of revenue reachable?
Market ceiling
Not at $399: that needs about 55% of locations. It depends on group ARPA from Scheduler, which is an assumption.
L7, L31
Why groups and not independents?
Segment evidence
Groups show 3x retention and buy 10+ locations per purchase. Independents churn more.
L15
Tell us about the PHI incident.
Compliance culture
What happened, root cause, changed controls, BAA status, counsel review.
L28, L35
Why did Northpoint get a discount?
Pricing power
About $318 per location (target $339, floor $209, list $399), traded for a 3-year term, two-wave rollout, de-identified data rights and reference rights, with an SLA and a fill-rate guarantee.
L37, L38
What do you get at a $40M exit?
Founder incentives
Series A takes its $12M preference; the seed converts. Maya receives about $9.46M.
L32
What would make you change course?
Judgment
The thresholds in the memo. If they are missed for two consecutive quarters, Relay cuts hiring and revisits the segment.
Decision memo
24
40 / DebriefPresentation, questions & the final decision
Reasoning traps
Negotiating the headline and losing on structure
Pushing from $48M to $54M pre while conceding a 10% pool in the pre-money, participation or seniority can leave the founders worse off. Compare offers by founder ownership and the payout at downside exits, not by headline price.
Answering the question you rehearsed
When asked about ClinicOS bundling, reciting the market-size slide leaves the actual concern, platform dependency, unresolved. Name the concern back, answer it directly, then give the evidence.
Treating the bridge as free time
A bridge dilutes the founders, lengthens the gap before the Series A and signals that the round was hard to raise. It pays only if the extra months can plausibly produce metrics worth a much higher price, about 43% higher in Relay's case.
25
40 / ReviewPresentation, questions & the final decision
What you can now explain
A delivered Relay Series A presentation, a question log with model answers and gaps, and a signed-off decision memo on the term sheet (accept, negotiate or bridge) with the supporting numbers.
A term-sheet decision compares options on founder ownership, payouts at downside exits and execution risk, not on the headline pre-money.
Strong answers to investor questions are direct, evidence-backed and explicit about what is not yet known, and each one links back to the claim it tests.
The final decision memo names the action, the owner, the conditions and the evidence that would reverse it, which makes the recommendation revisable rather than rhetorical.
26
Check your understanding
Can the audience understand, question and act on the decision?
Score
Question 1
As offered ($12M at $48M pre-money, no pool top-up), what do Maya and Daniel own together after the Series A, given 58.47% after the seed?
The Series A buys 12/60 = 20%, so every prior holder is multiplied by 0.8: 58.47% x 0.8 = 46.78%. The 43.85% figure is the 25% re-trade case, and 58.47% ignores dilution entirely.
Question 2
The lead's VC method says it needs 25% now if a Series B is expected to take 20%. If it insisted on 25% for the same $12M, what pre-money valuation would that imply?
Post-money = 12 / 0.25 = $48M, so pre-money = 48 - 12 = $36M. The tempting $48M answer confuses that post-money figure with the offered pre-money. The gap from $48M to $36M pre is the re-trade risk the founders should anticipate.
Question 3
A partner asks: 'At a $40M sale, what does the Series A receive?' The Series A holds 1x non-participating preferred ($12M) and would own 21.74% of outstanding shares as common (20% fully diluted; unissued pool shares receive nothing). What is the correct answer?
Non-participating preferred takes the greater of its preference or its as-converted share: max($12M, 21.74% x $40M = $8.70M) = $12M. Adding 21.74% of the remainder on top describes participating preferred, which this term sheet does not grant.
Question 4
Instead of signing, Relay raises an illustrative $3M post-money SAFE at a $50M cap (6%) and plans a Series A of $12M later. Roughly what pre-money must that later round reach for the founders to end with the same 46.78%?
Founders = 58.47% x 0.94 x P/(P+12). Setting this equal to 46.78% gives P/(P+12) = 0.851, so P = about $68.6M. The bridge must buy a 43% higher price just to break even on dilution, before counting execution and signaling risk.
Question 5
A partner asks, 'Will groups still be renewing in year three?' Relay's oldest group cohort is 14 months old. Which response is best?
Answer the question asked, state what is observed and keep the unknown as unknown. A forecast and a quote do not address renewal. One 3-year contract covers one customer and postpones the renewal question; it does not answer it.
Question 6
The lead proposes keeping the $48M pre-money but enlarging the unallocated pool to 10% post-money, included in the pre-money. What is the effect for Relay's existing holders?
When new pool shares sit inside the pre-money, existing holders alone absorb them. That lowers the price per share to about $2.73 from $2.81, and existing shares are effectively valued at about $46.7M. The headline number hides this, which is why pool size should be tied to a hiring plan.
Workbook
Can the audience understand, question and act on the decision?
Module output: A negotiation brief, package comparison and individual decision portfolio.
Sources
Materials this lesson draws on
Original pages and full documents are in the Library edition.